Update on Drugs and Drug News: January-February 2015

Update on Apremilast tablets (Otezla®), Collagenase clostridium histolyticum for injection (Xiaflex®), Afamelanotide 16 mg subcutaneous bioresorbable implants (Scenesse®), Clindamycin phosphate 1.2% + benzoyl peroxide 3.75% gel (Onexton™), Dupilumab SC injection, Apremilast tablets (Otezla®).

Medicated Shampoos are Effective in Many Scalp Conditions

Scalp conditions such as itchy scalp, dandruff, seborrheic dermatitis, and scalp psoriasis are common. The emotional effect these complaints cause are often ignored or trivialized, but as dermatologists we should appreciate the relief that appropriate advice and treatment will bring to our patients.

Novel Agents for Intractable Itch

There exists a multitude of medical conditions that cause intractable itch, or pruritus. These novel antipruritic agents will be explored in this review.

Topical Metronidazole for Rosacea

Rosacea is relatively common, typically occurring in individuals of Northern European and Celtic origin between 30 and 50 years of age. It is more common in women, but may be more severe in men. Currently there is no cure available for rosacea, but it can be controlled with topical and oral drug therapy.

US FDA Advisory Committee Meetings Held to Discuss Isotretinoin, Safety Issues and a New Accutane Formulation

There is no drug that has provided as much therapeutic benefit for 12 million acne patients as this retinoid has done in the past 18 years following its introduction. However, it is a retinoid and, therefore, a teratogen.

Update on Drugs & Devices: March-April 2022

This update covers Adalimumab biosimilar - Yuflyma™ (Celltrion Healthcare), Adalimumab biosimilar - Simlandi™ (Alvotech/JAMP Pharma), Abrocitinib tablet - Cibinqo® (Pfizer), Upadacitinib tablet - Rinvoq® (AbbVie), Risankizumab-rzaa SC injection - Skyrizi® (AbbVie), and HA-based dermal filler - Juvéderm® Volbella® XC (AbbVie/ Allergan Aesthetics).

Adverse Reactions to Herbal Therapy in Dermatology

There are many herbal therapies available for dermatological diseases that patients have already begun to discover. Dermatologists must be educated not only in the benefits of these therapies, but must also be aware of some of the risks and adverse effects.

Moisturizers and Cleansers in the Management of Skin Conditions Caused by Personal Protective Equipment and Frequent Handwashing

Routine moisturization with non-irritating, pH-adjusted, ceramide-based products and gentle cleansing with a pH-adjusted cleanser can treat the unique dermatological challenges posed by COVID-19.

The Role of the Dermatologist in Identification and Treatment of the Early Stages of Psoriatic Arthritis

Early diagnosis of psoriatic arthritis (PsA) is essential for preventing disease progression and joint destruction. We will review the presentation and temporal relationship of psoriasis and PsA, the diagnosis, classification, and management and the role of the dermatologist.

Treatment of Toxicodendron Dermatitis (Poison Ivy And Poison Oak)

Toxicodendron dermatitis results from a reaction to an oil soluble oleoresin that is present in many parts of the poison ivy and poison oak plants. Prophylactic measures and treatments are discussed.

Pimecrolimus 1% Cream (Elidel®) For Atopic Dermatitis

Pimecrolimus is an immunomodulating medication that inhibits production of inflammatory cytokines in the skin and this compound was specifically developed for the treatment of inflammatory skin diseases.

Age-related Percutaneous Penetration Part 2: Effect of Age on Dermatopharmacokinetics and Overview of Transdermal Products

Transdermal drug delivery allows for a constant rate of drug administration. This second part highlights the importance of elderly patient care, and consideration for patients who may be using multiple drug treatments.

Update on Drugs and Drug News: May 2011

Update on drugs, approval dates, and comments. Belimumab (Benlysta®), Ipilimumab (Yervoy™), Imiquimod 3.75% Cream (Vyloma™) are covered.

Brodalumab: A Review of Safety

Interleukin (IL)-17 is important in the pathophysiology of psoriasis and has proven to be an effective therapeutic target. As brodalumab enters the marketplace, a review of this important biologic, its safety profile, and discussion of possible adverse effects is in order.

The Current Management of Delusional Parasitosis and Dermatitis Artefacta

Psychocutaneous disorders involve a unique and somewhat difficult patient population. This paper describes an effective interpersonal approach and appropriate drug therapy for patients with delusional disorders and dermatitis artefacta.

Update on Drugs and Drug News: March-April 2018

Update on Drugs & Devices March and April 2018: Hydrogen peroxide topical solution Eskata™, Mepolizumab for SC injection Nucala® GSK, Brentuximab vedotin for IV use Adcetris®, CoolSculpting®, (PDF) patch DeScribe® PFD Patch, Adhesive patch for melanoma detection Pigmented Lesions Assay (PLA)

Update on Drugs and Drug News: March 2012

Update on drugs, approval dates, and comments. Ingenol mebutate gel (0.015%, 0.05%) Picato® and Vismodegib capsule (Erivedge™) are covered.

The Therapeutic Potential of Cannabinoids in Dermatology

Learn about cannabinoids influence on skin growth control, homeostasis, melanoma, acne, pruritus, inflammation, atopic dermatitis, and other skin conditions.

Drug Treatments Introduced in 1998

Drug Treatments Introduced in 1998

Update on Drugs and Drug News: October 2011

Update on drugs, approval dates, and comments. IncobotulinumtoxinA injection (Xeomin®), Vemurafenib tablets (Zelboraf™ cobas®), Icatibant injection (Firazyr®) are covered.

Rosacea: An Update in Diagnosis, Classification and Management

This review details the rosacea phenotype approach to diagnosis and classification, and summarizes current evidence-based treatment recommendations for individual features.

The Treatment of Primary Focal Hyperhidrosis

Primary focal hyperhidrosis afflicts a significant number of patients in the United States and greatly impacts their quality of life. Treatment decisions should take into consideration disease location, severity and patient preference.

Management of Primary Small-Vessel Vasculitis

Small-vessel vasculitides (SVV) are a group of disorders that occur due to primarily systemic inflammation or as sequelae of an infection, malignancy, or other rheumatic disease.

Prevention of Polymorphous Light Eruption and Solar Urticaria

Polymorphous light eruption (PLE) and solar urticaria (SU) are two photodermatoses that are induced by ultraviolet radiation and sometimes by visible light. This article will review the various means of preventing PLE and SU with an emphasis on the role of sunscreens.

Labeling Laws for Personal Care Products: Potential Pitfalls for The Consumer

Consumers of personal care products must be made aware of the potential pitfalls that arise from current labeling practices and regulations. For example, terms such as “hypoallergenic“, “sensitive skin“, and ...

The Evolving Role of Biologics in the Treatment of Pediatric Psoriasis

The exact role of biologics in the treatment of pediatric psoriasis remains undefined but evolving. This article will provide a summary of the cumulative pediatric safety and efficacy data for the anti-tumor necrosis factor-alpha (TNF-α) agents and interleukin (IL)-12 and IL-23 (IL12/23) pathway inhibitor.

Treatment of Acne Scarring

Acne scarring is common but surprisingly difficult to treat. Scars can involve textural change in the superficial and deep dermis, and can also be associated with erythema, and less often, pigmentary change. In general, treatment of acne scarring is a multistep procedure.

Use of Tacrolimus Ointment in Vitiligo Alone or in Combination Therapy

Current treatments for vitiligo are largely unsatisfactory. Topical corticosteroids and phototherapy (narrow-band UVB and psoralen+UVA) are the most prescribed, however, these therapies are often not effective and have important side-effect, especially when used for a long time.

Update on Drugs and Drug News: Number 2 2000

Updates on: Estradiol Transdermal System Vivelle Levofloxacin Tablets/Injection Levaquin Tablets/Injection Tretinoin Cream Renova 0.02% Tretinoin Cream Renova 0.05% Butoconazole Nitrate Gynazole 2% vaginal cream Docosanol 10% Cream Tacrolimus Ointment

Topical Clascoterone for Acne Vulgaris

Clascoterone 1% cream represents a novel and promising therapeutic agent in the management of acne vulgaris for individuals ≥12 years of age. Notably, this topical agent was not observed to have significant systemic effects seen with systemic anti-androgenic agents.

Update on Drugs and Drug News: July 2012

Update on drugs, approval dates, and comments. CIP-Isotretinoin (Absorica™), Tazarotene 0.1% foam (Fabior™), Butoconazole nitrate 2% vaginal cream, Multisource radiofrequency aesthetic device (Glow by EndyMed™), Low-level laser for circumferential upper arm reduction (Zerona®) are covered.

Update on Drugs & Devices: March – April 2020

This update covers Tazemetostat tablets/Tazverik™ (Epizyme, Inc.), Tazarotene lotion 0.045%/Arazlo™ (Ortho Dermatologics, Bausch Health) and Rituximab biosimilar for IV injection/ABP 798 (Amgen, Allergan).

Vitamin B Derivative (Nicotinamide) Appears to Reduce Skin Cancer Risk

Recent studies have demonstrated the role of Vitamin B Derivative (Nicotinamide), in both topical and oral forms, as a chemopreventive agent against skin cancer.

Nanodermatology: A Glimpse of Caution Just Beyond the Horizon – Part II

Nanotechnology applies the unique properties of matter on the nanoscale (1000 nm and smaller) for the purposeful design of new materials. Dermatology is already one of the leading beneficiaries of nanotechnology.

A Practical Guide to Dermatological Drug Use in Pregnancy

Although the developing fetus was once considered protected from the outside world, we now know that it can potentially be affected by any medication given to the mother. Therapeutic options available for these patients will be discussed.

POPULAR